Insider Transaction Report for Autolus Therapeutics plc

Robert Azelby, a director at Autolus Therapeutics plc, acquired 31,667 Restricted Share Units (RSUs) and 47,500 share options on June 29, 2026. The RSUs, representing contingent rights to one American Depositary Share each, vest on June 29, 2027. The share options, with a conversion price of $1.61 per share, vest in twelve equal monthly installments starting July 29, 2026. All transactions were reported on Form 4, with the report filed on July 1, 2026. Azelby holds these securities directly.